Accustem Sciences Q3 2026 Results: Net Loss of $1.87M, Loss Widens
Accustem Sciences Inc. reported a net loss of $2,608,351 for the nine months ended September 30, 2026, significantly higher than the $1,241,708 loss in the prior year period, primarily due to a $1.5 million acquired in-process research and development expense. The company faces substantial liquidity concerns with a working capital deficit of $5,980,129 and continues to rely on related party financing to fund its clinical-stage diagnostic operations.
- Key figure
- Net loss $1.87M